PipelineReview.com15h
New drug application for core product trastuzumab botidotin accepted by the National Medical Products Administration
CHENGDU, China I January 07, 2025 I The board (the “Board”) of directors (“Directors”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) is ...
PipelineReview.com15h
Kelun-Biotech’s anti-PD-L1 (tagitanlimab) receives NMPA approval for marketing
CHENGDU, China I January 20, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) has received marketing authorization in China from ...
PipelineReview.com16h
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI, China I January 20, 2025 I YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the ...